Johnson & Johnson (JNJ) Offering Possible 8.7% Return Over the Next 24 Calendar Days

Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $145.00 short put and a strike $135.00 long put offers a potential 8.7% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $145.00 by expiration. The full premium credit of $0.80 would be kept by the premium seller. The risk of $9.20 would be incurred if the stock dropped below the $135.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.

The RSI indicator is at 70.75 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Johnson & Johnson

The Cold, Hard Barriers to Getting Vaccinated
Sun, 20 Dec 2020 22:00:20 +0000
(Bloomberg Opinion) — Doctors, nurses and other essential workers are getting vaccinated against Covid-19 in the U.S. and U.K. Yet in Asia, where several countries led the way in reining in the viral outbreak, there are few signs that detailed distribution plans are ready to be implemented. Supplies are limited and unknowns plentiful. Governments need to jump-start the process to get shots into arms. In most cases, however, their capacity to distribute the vaccine is a constraint or simply doesn’t exist.Some nations have signed on to procurement and advanced purchasing plans from vaccine manufacturers. Others are working on collaborations and homegrown options. But everywhere, the need to maintain optimal temperatures for certain vaccines raises hard issues, such as cold-storage warehouses and adequate last-mile delivery. McKinsey & Co. has said that just 1% of existing vaccine distribution networks is set up for cold-chain requirements that keep the new Covid-19 serums viable — temperatures at the frozen or deep frozen(4) levels. Most low- and middle-income countries can’t afford the infrastructure investment in a short period. Many may have to borrow from multilateral organizations like the World Bank. That means limited funding and one shot at getting it right.So how do governments in their second, third or even fourth waves prepare? Most are using immunization plans from previous vaccine rollouts. These were typically targeted at pregnant women and children, which are not the populations at the top of the list in this pandemic. India’s universal immunization program covers 26 million infants and 29 million mothers annually and is the largest of its kind in the world. Yet experts say it won’t be sufficient.Andrea Taylor of Duke University’s Global Health Institute says distribution plans will be based on four scenarios, rooted in refrigeration temperatures. Most mid-income and poorer countries have ruled out vaccines that need deep freezing, she says, and are preparing for the standard refrigeration scenario. Eventually, heat-stable vaccines and nasal spray formats could be the way.  None of this is easy, but vaccine rollouts have always been more problematic in non-wealthy countries. Almost two decades after the hepatitis B vaccine came out, the population covered was estimated at around 90% in the Americas and just 28% in Southeast Asia, where the disease is a far larger problem.South Korea’s concurrent experience with a campaign to inoculate 30 million people against influenza shows that there’s always room for error, even in countries with well-established plans. The government recalled more than 1 million doses, to be on the safe side, after photos circulated online of boxes of vaccines stacked in parking lots. Health authorities said that they found no direct causal links between the flu vaccine and the deaths of more than 100 people who died after getting it. But the panic means that only 19 million people have so far taken the shots. Singapore suspended its use.South Korea was an early global model for tracking, tracing and testing the rapid spread of Covid-19, but it’s facing another surge in cases. Prime Minster Chung Sye-kyun says authorities will come up with a plan allowing pre-purchased vaccines to be acquired in the first quarter of 2021; the country has said it’s in the process of securing doses from companies including AstraZeneca Plc, Moderna Inc., Pfizer Inc. and Johnson & Johnson’s Janssen Pharmaceuticals Inc. But the health minister has said there’s no hurry “when the risks have not been verified yet.”That’s a fair concern. However, Covid-19 doesn’t allow the luxury of time of the typical manufacturing supply chain. “We cannot afford a sequential process,” David Simchi-Levi, director of the MIT Data Science Lab, told Supply Chain Dive. “We need to start the manufacturing capacity today, and the problem is it requires significant investment.”Then there’s the more mundane but crucial matter of trade facilitation: how to get vaccines across national borders. Think of this as the software of trade – approvals, customs, tariffs, rules and regulations on inspection services, certification, permissions, how packages are handled, and the intellectual property rules. An Asian Development Bank study in 2017 found that getting it right increases immunization rates, especially in low-income countries.A look at the trade of medicines, totaling almost $50 billion globally, shows why the process isn’t so straightforward. Some regulations seem absurd in a time of global pandemic. For instance, the average applied tariff for hand soap is 17%, while some World Trade Organization members put it as high as 65%. The average tariff on protective supplies is 11.5%.In May, Canada invested more than $40 million to upgrade a vaccine production facility in Montreal “to ensure readiness for Canadian bioprocessing of potential vaccine candidates as they become available.” It was supposed to produce 250,000 doses by November. Then a partnership with China’s CanSino Biologics Inc. fell apart because Chinese customs authorities held up the first shipment of trial doses to Canada.Without a timely and straightforward way to get a vaccine, Covid-19 won’t be eradicated. And the economic recovery that we see signs of won’t really take off.(1) Frozen: -15to -25 degrees celsius. Deep frozen: -60 to -80 degrees celsius.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Anjani Trivedi is a Bloomberg Opinion columnist covering industrial companies in Asia. She previously worked for the Wall Street Journal. For more articles like this, please visit us at now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now
Sun, 20 Dec 2020 11:09:00 +0000
There are also a few stocks of the companies making these vaccines that are unparalleled in some ways. Here are three extraordinary coronavirus vaccine stocks that you can buy right now. Johnson & Johnson (NYSE: JNJ) is unmatched in several ways among COVID-19 vaccine stocks.

2 COVID Vaccine Stocks With Key Results on the Way
Sat, 19 Dec 2020 12:07:00 +0000
Corrine Cardina: My last topic for us before we try to tackle a couple of Slido questions is turning to the companies that are next in line to cross this finish line, what do we know about the timeline for Johnson & Johnson (NYSE: JNJ) and AstraZeneca's (NASDAQ: AZN) phase 3 data? Johnson & Johnson has kept their information a little closer to the vest than a lot of these companies.

5 Top Stocks You Can Buy Now and Hold Forever
Sat, 19 Dec 2020 12:07:00 +0000
It's easy to buy a stock, but to hold it through market crashes requires immense willpower and patience. For example, did you know Waste Management (NYSE: WM) stock could have more than quadrupled your money in just the past decade? The company offers resilient business and steady dividend growth, both of which are here to stay for decades to come.

J&J (JNJ) Coronavirus Vaccine Candidate Study Fully Enrolled
Fri, 18 Dec 2020 18:52:06 +0000
Johnson & Johnson (JNJ) phase III study on its experimental COVID-19 single-dose vaccine candidate is now fully enrolled.

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.